Weighted analysis of symptom profile by vaccination status in positive SARS-CoV-2 cases: observational study in Sao Goncalo, Brazil
das Chagas, R. R.; Freitas, H. R.; Cardozo, S. V.
Show abstract
This study investigates symptom associations in SARS-CoV-2 positive individuals based on vaccination status. Unvaccinated individuals exhibited significantly higher odds of experiencing severe symptoms, including fever > 38.5{square}{degrees}C (logOR = 3.64, 95% CI: 1.52-5.77, p = 0.0008), rhinitis (logOR = 2.94, 95% CI: 0.82-5.05, p = 0.0065), headache (logOR = 2.17, 95% CI: 0.06-4.28, p = 0.0436), and myalgia (logOR = 3.25, 95% CI: 1.17-5.34, p = 0.0023). Conversely, unvaccinated individuals were less likely to report cough (logOR = -2.44, 95% CI: -4.53 to -0.34, p = 0.0226), potentially reflecting behavioral factors related to vaccine hesitancy. Among vaccinated participants, symptom profiles varied by vaccine type. Both Oxford-AstraZeneca and Pfizer-BNT162b2 vaccines were associated with increased odds of loss of smell (logOR = 0.81 and 1.47, respectively) and loss of taste (logOR = 0.75 for Oxford-AstraZeneca). Additionally, the Oxford-AstraZeneca vaccine was linked to dyspnea (logOR = 0.85, 95% CI: 0.02-1.69, p = 0.0449). These findings suggest that vaccination reduces the likelihood of severe systemic and respiratory symptoms while influencing specific symptom manifestations in breakthrough cases. Ongoing research is essential to understand vaccine-specific immune responses and their impact on clinical outcomes.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial 94%
- Persistent health issues, adverse events of significant concern, and effectiveness of COVID-19 vaccination- findings from a real-world cohort study of healthcare workers in north India 94%
- Tracking Immunity: Increased number of COVID-19 boosters increases the longevity of anti-RBD and anti-RBD neutralizing antibodies 94%
Similar papers in this journal
- Efficacy and Safety of an Inactivated Whole-Virion SARS-CoV-2 Vaccine (CoronaVac) in Brazilian Healthcare Professionals: The PROFISCOV Trial 95%
- Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study 94%
- Dynamics of antibody responses, cellular immunity, and breakthrough infections among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine 94%
Similar papers in this journal
- Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study 94%
- Neutralizing antibodies following three doses of BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron predominant wave 93%
- Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022 93%
Similar papers in this journal
- Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study 94%
- Time-Varying Effectiveness of Three Covid-19 Vaccines in Puerto Rico 93%
- Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the Omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study 92%
Similar papers in this journal
- Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru 94%
- COVID-19 vaccine effectiveness against laboratory confirmed symptomatic SARS-CoV-2 infection, COVID-19 related hospitalizations and deaths, among individuals aged 65 years or more in Portugal: a cohort study based on data-linkage of national registries February-September 2021 94%
- Viral and host factors associated with SARS-CoV-2 disease severity in Georgia, USA 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.